NCT01863745 - Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2013

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

nilotinib

Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.

Trial Locations (11)

464 8681

Novartis Investigative Site, Nagoya

277 8577

Novartis Investigative Site, Kashiwa

501-1194

Novartis Investigative Site, Gifu

060 8648

Novartis Investigative Site, Sapporo

241-8515

Novartis Investigative Site, Yokohama

860-8556

Novartis Investigative Site, Kumamoto

980 8574

Novartis Investigative Site, Sendai

701-0192

Novartis Investigative Site, Kurashiki

540-0006

Novartis Investigative Site, Osaka

565 0871

Novartis Investigative Site, Suita

104 0045

Novartis Investigative Site, Chuo Ku